NGX-4010 for the Treatment of Postherpetic Neuralgia

Phase 2

Completed

• Conditions: Herpes Zoster; Neuralgia; Pain; Peripheral Nervous System Diseases; Shingles

• Registration Number: NCT00061776
• Lead Sponsor: NeurogesX

Brief Summary

The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).

Detailed Description

Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin).

Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.

Study Timeline

• Study First Submitted: 2003-06-03
• Study First Submitted QC: 2003-06-03
• Study First Posted: 2003-06-04
• Status Verified: 2008-03
• Last Update Submitted: 2008-03-04
• Last Update Posted: 2008-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

NeurogesX Investigational Site; 🇺🇸 Tacoma, Washington, United States